10-Q: Hi-Great Group Holding Company Reports Q3 2024 Results, Revenue Declines Amidst Strategic Shift

Hi-Great Group Holding Company's Q3 2024 results show a decrease in revenue and a net loss, as the company focuses on a new business plan and the cosmetic sector.

Summary

• Hi-Great Group Holding Company reported its financial results for the quarter ended September 30, 2024.
• The company experienced a decrease in sales, with $55,700 for the nine months ended September 30, 2024, compared to $154,792 for the same period in 2023.
• Cost of sales also decreased to $26,495 for the nine months ended September 30, 2024, from $141,632 in the prior year.
• The company's net loss for the nine months ended September 30, 2024, was $28,617, an improvement from the $95,555 loss in the same period of 2023.
• Professional fees increased to $34,600, up from $31,250, due to higher legal and audit expenses.
• General and administrative expenses decreased to $8,302 from $63,819, attributed to lower revenue.
• The company had an interest expense of $1,138 for the nine months ended September 30, 2024.
• The company's accumulated deficit is $867,595.
• The company is focusing on a new business plan related to the KRAS gene and expanding into the cosmetic sector.

Sentiment

Score: 4

Explanation: The document shows a mixed picture with a significant revenue decline but an improved net loss. The strategic shift is positive, but the company's financial position and internal control weaknesses are concerning.

Positives

• The company's net loss decreased significantly from $95,555 to $28,617 year-over-year.
• General and administrative expenses decreased substantially, indicating cost control.
• The company is focusing on a new business plan related to the KRAS gene, which could be a high-growth area.
• The company is expanding into the cosmetic sector, which could provide a new revenue stream.

Negatives

• Sales decreased significantly from $154,792 to $55,700 year-over-year.
• The company continues to operate at a loss, with a net loss of $28,617 for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $867,595.
• Professional fees increased, indicating higher operating costs.

Risks

• The company is a development stage enterprise and has not yet established an ongoing source of revenues sufficient to cover its operating costs.
• The company is dependent on debt and equity financing to fund its operations.
• There is no assurance that the company will be able to raise additional equity capital or be successful in the development and commercialization of its products.
• The company's disclosure controls and procedures were not effective for the quarter ended September 30, 2024, due to a lack of an audit committee and segregation of duties.
• The company is subject to various loss contingencies arising in the ordinary course of business.

Future Outlook

The company is focusing on a new business plan related to the KRAS gene and expanding into the cosmetic sector as a sustainable revenue platform.

Management Comments

• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management believes that it will be successful in its capital formation and planned operating activities.

Industry Context

The company's shift towards the KRAS gene and the cosmetic sector reflects a move towards high-growth areas within the biotechnology and consumer goods industries, potentially aligning with market trends for personalized medicine and natural beauty products.

Comparison to Industry Standards

• The company's revenue decline is concerning when compared to industry averages, which often show growth in the health supplement and cosmetic sectors.
• The company's net loss, while improved, is still significant and needs to be addressed to achieve industry-standard profitability.
• The lack of an audit committee and segregation of duties is a significant deficiency compared to standard corporate governance practices in publicly traded companies.
• The company's reliance on related party transactions is higher than industry norms, which could raise concerns about potential conflicts of interest.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a licensing agreement with SellaCare, Inc., which is controlled by the company's majority shareholder, requiring a 25% royalty payment on gross revenues.
• The company leases land from Sella Property, LLC, an entity controlled by the company's majority shareholder, with annual rent payments of $30,000.
• The company has various loan and payable transactions with related parties.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the company's continued losses.
• Employees may be affected by the company's strategic shift and potential restructuring.
• Customers may be impacted by changes in the company's product offerings.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on its new business plan related to the KRAS gene.
• The company will expand into the cosmetic sector.
• The company will seek additional funding through an equity funding facility.

Key Dates

Keywords

KRAS gene, cosmetics, herbal supplements, agritourism, licensing agreement, financial results, net loss, revenue, operating expenses, related party transactions